

Clinical Policy: Cenegermin-bkbj (Oxervate)

Reference Number: PA.CP.PMN.186

Effective Date: 01.19

Last Review Date: 01/2022

[Revision Log](#)

Description

Cenegermin-bkbj (Oxervate™) is recombinant human nerve growth factor (rhNGF).

FDA Approved Indication(s)

Oxervate is indicated for the treatment neurotrophic keratitis.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health & Wellness® that Oxervate is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Neurotrophic Keratitis (must meet all):

1. Diagnosis of stage 2 or 3 neurotrophic keratitis;
2. Prescribed by or in consultation with an ophthalmologist;
3. Age \geq 2 years;
4. Dose does not exceed 1 vial per affected eye per day.

Approval duration: 8 weeks

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53.

II. Continued Therapy*

A. Neurotrophic Keratitis (must meet all):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met all initial approval criteria or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 1 vial per affected eye per day.

Approval duration: Up to a total of 8 weeks

****Requests for retreatment of the same eye within one year will be reviewed on a case-by-case basis based on chart documentation of previous response to therapy and clinical rationale for re-treatment***

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – PA.CP.PMN.53 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

rhNGF: Recombinant human nerve growth factor

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- Definitions of neurotrophic keratitis stages 1-3:
 - Stage 1: Punctate keratopathy and/or corneal epithelial hyperplasia and irregularity.
 - Stage 2: Persistent corneal epithelial defect (PED), typically oval or circular in shape, with smooth and rolled edges.
 - Stage 3: Corneal stroma and a corneal ulcer is observed. Corneal ulceration tends to progress to perforation and/or stromal melting if not promptly and properly treated.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Neurotrophic Keratitis	1 drop in the affected eye every 2 hours six times a day for 8 weeks	6 drops per affected eye per day

VI. Product Availability

Ophthalmic solution: 0.002% (20 mcg/mL)

VII. References

1. Oxervate Prescribing Information. Milan, Italy: Dompe farmaceutici S.p.A; October 2019. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761094s001lbl.pdf. Accessed October 4, 2021.

2. European Medicines Agency, Science Medicines Health/Assessment Report. Available at: https://www.ema.europa.eu/en/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf Updated May 18, 2017. Accessed October 4, 2021.
3. Bunya V, Woodward N, Rabiolo A, et al. Neurotrophic Keratitis. Last updated December 2020. Available at: https://eyewiki.aao.org/Neurotrophic_Keratitis. Accessed October 4, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2019 Policy created	01.19	02.19
1Q 2020 annual review: Added requirement for stage 2 and 3 disease to initial approval criteria; references reviewed and updated.	01/2020	
1Q 2021 annual review: no significant changes; references reviewed and updated.	01/2021	
1Q 2021 annual review: references reviewed and updated.	01/2022	